CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2009-08-05): Jury out on added benefit of combined DTP-HBV-HIB vaccine

Clinical

Jury out on added benefit of combined DTP-HBV-HIB vaccine

Last Updated: 2009-08-05 13:30:35 -0400 (Reuters Health)

NEW YORK (Reuters Health) - It is unclear whether the combined diphtheria-tetanus-pertussis, hepatitis B, and Haemophilus influenzae type B (DTP-HBV-HIB) vaccine is as effective as the separate DTP-HBV and HIB vaccine, researchers say.

Based on the pooled results of 18 studies, "We could not conclude that the immune responses elicited by the combined vaccine were different from, or equivalent to, the separate vaccines," the researchers wrote in the July 8 issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research.

The World Health Organization recommends that routine infant vaccination programs use the combined DTP-HBV-HIB vaccine, yet the effectiveness and safety of adding a conjugate HIB vaccination to the DTP-HBV vaccine, compared with separate administrations, has yet to be systematically assessed, the authors note.

To investigate, Dr. Edna Bar-On, of Rabin Medical Center in Petah-Tiqva, Israel and colleagues and performed a meta-analysis of 18 randomized or quasi-randomized clinical trials involving a total of 10,374 children. The studies compared vaccination of any combined DTP-HBV-HIB vaccine with or without three types of inactivated poliovirus or concomitant oral polio vaccine compared with separate vaccines or placebo, administered to infants aged up to 2 years.

According to the investigators, there were no data on the primary outcome (prevention of disease); all of the studies used reactogenicity (adverse events) and immunogenicity.

With the combined vaccine, they found some evidence of lower immune responses for HIB and HBV, and more local adverse reactions, although "these differences rely mostly on one study each," they caution.

The reviewed studies "did not use an intention-to-treat analysis and we were uncertain about the risk of bias in many of the studies," Dr. Bar-On and colleagues add. "These results are therefore inconclusive."

There were no significant differences in immunogenicity for pertussis, diphtheria, polio and tetanus. Serious adverse events were comparable between the vaccines, while minor adverse events were more common with the combined vaccine.

Cochrane Database Syst Rev 2009.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.